Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-methylalanyl-3-methylvalyl-4-phenoxy-N-(1,2,3,4-tetrahydronaphthalen-1-yl)prolinamide
- Development stage
- Unknown
- Modality
- Peptides, Small Molecules
01
Overview
N-methylalanyl–3-methylvalyl–4‑phenoxy‑N‑(1,2,3,4‑tetrahydronaphthalen‑1‑yl)prolinamide is a synthetic peptide-like small molecule belonging to the class of oligopeptides and carboxylic acid derivatives[6][4][9]. It has been studied as an experimental compound and is not approved for any indication. The compound has been referenced in pharmaceutical databases such as DrugBank and PubChem but lacks detailed information on its mechanism of action or clinical development. Some sources suggest it may interact with E3 ubiquitin-protein ligase XIAP as a potential target[5][3], but its precise pharmacological activity remains uncharacterized.
- Other names
- N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE1-[3,3-dimethyl-2-(2-methylamino-propionylamino)-butyryl]-4-phenoxy-pyrrolidine-2-carboxylic acid(1,2,3,4-tetrahydro-naphthalen-1-YL)-amide(2S,4S)-1-[ (2S)-3,3-dimethyl - 2 - [ ( 2S ) - 2 -( methylamino ) propanamido ] butanoyl ] - 4 - phenoxy-N-[ ( 1R ) - 1 , 2 , 3 , 4-tetrahydronaphthalen - 1 - yl ] pyrrolidine - 2-carboxamide
02
Targets
XIAP
Beyond the preview
Go deeper on N-methylalanyl-3-methylvalyl-4-phenoxy-N-(1,2,3,4-tetrahydronaphthalen-1-yl)prolinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-methylalanyl-3-methylvalyl-4-phenoxy-N-(1,2,3,4-tetrahydronaphthalen-1-yl)prolinamide.